Navigation Links
A safer, more effective morphine may be possible with Indiana University discovery
Date:3/24/2011

INDIANAPOLIS An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.

The researchers say the finding in animal models may ultimately make morphine a safer and more effective drug.

Traditionally opioids were used to relieve pain following surgery, from cancer and at the end of life. Today opioids are used widely for chronically painful conditions like osteoarthritis and back pain and may need to be prescribed for decades.

Morphine, the gold standard for controlling moderate to severe pain, has debilitating side effects including reduced respiration, constipation, itching and addiction. Patients also develop a tolerance to morphine which can lead to a complicated spiral.

"In addition to the recognized side effects, morphine actually creates sensitivity and causes more pain through inducing an inflammatory response in the body," said first author Natalie Wilson, a National Science Foundation Fellow at the IU School of Medicine.

This increased sensitivity is clinically known as opioid-induced hyperalgesia (OIH). Frequently, patients receiving opioids for pain control may actually become more sensitive to certain painful stimuli necessitating an increased opioid dosage. OIH may also represent one of many reasons for declining levels of analgesia while receiving opioids or a worsening pain syndrome.

"The drug itself is producing its own new pain," said Fletcher A. White, Ph.D., Vergil K. Stoelting Professor of Anesthesia and director of Anesthesia Research at the IU School of Medicine. "I tend to view it as an injury as it appears to be creating another pain."

Dr. White explained that morphine sets into motion a cascade of events, one of which is to increase molecular communication to and from the nerves by a protein known as CXCR4. This increase in CXCR4 signaling contributes to a neuroinflammatory response causing increased sensitivity and additional pain.

Drs. Wilson and White and colleagues administered AMD3100, an orphan drug known to block the CXCR4 response, to rats. By halting the signaling process, the researchers interrupted the OIH response, Dr. White explained. "If this translates appropriately in people, this application would likely make morphine a safer, more effective drug for chronic pain control."


'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Electronic Health Information Leader Says Physician Practice Redesign is Vital Next Step Towards Safer, More Effective Care Delivery
2. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
3. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
4. Toys Getting Safer, But Dangers Still Lurk: Report
5. Secrets of plant warfare underpin quest for safer, more secure global food supply
6. Low forms of cyclin E reduce breast cancer drugs effectiveness
7. Gastric Banding Most Effective for Obese Teens
8. Neuroimaging study may pave way for effective Alzheimers treatments
9. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
10. Charging less for more effective treatments could reduce health care costs while improving health
11. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A safer, more effective morphine may be possible with Indiana University discovery
(Date:7/27/2017)... ... July 27, 2017 , ... HIMSS ... will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s foremost ... Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, The ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs ... freeze drying samples and a lengthy freeze dry cycle are a few common challenges ... drying techniques, as well as new accessories and advancements in laboratory freeze dryers that ...
(Date:7/26/2017)... ... July 26, 2017 , ... The ... Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 – ... challenges faced by process validation professionals and statisticians today. , “These conferences ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is excited to announce the 106 ... Global Ambassador Program. , Established in 2005, the Team Type 1 Foundation has ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
Breaking Medicine Technology: